Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > On GLP-1 agonists US Senate passes anti-patent thicket bill

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 16, 2024 7:47pm

102 Views

Post# 36135823

RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

As a result of the US Senate's passing of the anti-patent thicket bill on July 12, 2024, a common tactic of layering patents on top of a single producr to extend marketing protections, "process" or "utility" patents that had been used in the past and filed on incremental improvements of the original product in an effort to extend patent exclusively, will no longer hold precedent in the same manner as before.

https://www.biospace.com/policy/senate-unanimously-passes-bill-to-reduce-big-pharma-patent-thickets-increase-competition

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario